AI-Driven EKG Screening for Dilated Cardiomyopathy (DCM-DETECT Trial)

Palo Alto (17 mi)

Overseen byRoy Small, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: N/A

Waitlist Available

Sponsor: Lancaster General Hospital

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.

Eligibility Criteria

This trial is for people with dilated cardiomyopathy who will invite their close family members to participate in mobile heart screening using an AI-enhanced electrocardiogram (EKG).

Inclusion Criteria

I am 18 years old or older.

I have been diagnosed with a type of heart failure not caused by blocked arteries and my heart's pumping ability is reduced.

I have at least one living adult close family member.

Exclusion Criteria

I was born with a heart defect.

My heart condition is due to a sudden or treatable cause.

I have a significant heart valve problem not caused by heart muscle disease.

My low heart pumping function is due to a blockage.

I have severe high blood pressure that hasn't been treated or can't be treated.

I have a condition that has caused my heart's pumping ability to decrease.

Treatment Details

The study is testing a new way to detect heart conditions using a portable device that records the electrical activity of the heart, enhanced by artificial intelligence.

1Treatment groups

Experimental Treatment

Group I: DCM ScreeningExperimental Treatment1 Intervention

Participants with dilated cardiomyopathy will invite their first-degree relatives to participate in DCM screening to examine the impact of an "Artificial Intelligent" (AI) enhanced 6lead (6L) mobile EKG in encouraging first degree relatives (FDR) of probands with a dilated cardiomyopathy (DCM) to obtain appropriate cardiac screening.